FiercePharma22h
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Reuters7d
GSK shares jump on $2.2 billion Zantac settlement
The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...
FierceBiotech1d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
India Infoline1d
Hindustan Unilever Ltd Company Summary
GSK CH India is the market leader in the Health Food Drinks (HFD) category, with iconic brands such as Horlicks and Boost, and a product portfolio supported by strong nutritional claims.The ...
Wall Street Journal7d
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK GSK1.11%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...
CNN7d
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...
Nasdaq7d
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...
The Financial Times7d
GSK’s problem is it has more than one source of pain
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...
MoneyWeek7d
GSK share price surges after $2.2bn Zantac drug settlement
GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly lower after it agreed a $2.2 billion settlement over lawsuits in the US, which alleged the drugmaker’s now ...
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor confidence in the company.
Wall Street Journal7d
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...